Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 4 boards, counting each seat separately. Longest: Becton Dickinson and Company, 3 years.
Becton Dickinson and Company
Director
QUALCOMM Incorporated
Director
Halozyme Therapeutics Inc.
Director
Kyntra Bio Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 5, 2026 | Halozyme Therapeutics Inc. | Grant or award | +3,796 | — | — |
| Mar 17, 2026 | QUALCOMM Incorporated | Grant or award | +2,563 | — | — |
| Mar 8, 2026 | QUALCOMM Incorporated | Option exercise | +2,355 | — | — |
| Mar 8, 2026 | QUALCOMM Incorporated | Sold back to the company | −759 | $135.69 | $102,989 |
| Jan 27, 2026 | Becton Dickinson and Company | Grant or award | +1,098 | — | — |
| May 1, 2025 | Halozyme Therapeutics Inc. | Grant or award | +4,165 | — | — |
| Apr 28, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −4,297 | $60.34 | $259,281 |
| Apr 28, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −200 | $61.00 | $12,200 |
| Apr 1, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −503 | $64.05 | $32,217 |
| Mar 18, 2025 | QUALCOMM Incorporated | Grant or award | +2,097 | — | — |
| Mar 9, 2025 | QUALCOMM Incorporated | Option exercise | +1,901 | — | — |
| Mar 3, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −1,795 | $57.93 | $103,984 |
| Mar 3, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −3,205 | $59.12 | $189,480 |
| Feb 10, 2025 | Becton Dickinson and Company | Open-market purchase | +1,500 | $233.62 | $350,430 |
| Feb 3, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −1,100 | $55.94 | $61,534 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.